Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study

World Journal of Gastroenterology

Volumn 17, Issue 8, 2011, Pages 1045-1050

  Yoshida, Keiko ^a   Hirokawa, Tomihiko ^a   Moriyasu, Fuminori ^a   Liu, Longzhong ^a   Liu, Guang Jian ^a   Yamada, Masahiko ^a   Imai, Yasuharu ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Animal model; Contrastenhanced ultrasonography; Liver tumor; Sorafenib; Ultrasound agent

Indexed keywords

PERFLUBUTANE; SONOVUE; SORAFENIB;

ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; ECHOGRAPHY; IMAGE ANALYSIS; LIVER PARENCHYMA; LIVER TUMOR; MALE; NONHUMAN; PILOT STUDY; TUMOR VOLUME;

EID: 79955934648     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i8.1045     Document Type: Article

References (12)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711
4. Maruyama H, Takahashi M, Ishibashi H, Okabe S, Yoshikawa M, Yokosuka O. Changes in tumor vascularity precede microbubble contrast accumulation deficit in the process of dedifferentiation of hepatocellular carcinoma. Eur J Radiol 2010; 75: e102-e106
5. Choi BI. Doppler and harmonic ultrasound for hepatocellular carcinoma. Hepatol Res 2007; 37 Suppl 2: S172-S177
6. Lavisse S, Lejeune P, Rouffiac V, Elie N, Bribes E, Demers B, Vrignaud P, Bissery MC, Brulé A, Koscielny S, Péronneau P, Lassau N. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrastenhanced ultrasonography. Invest Radiol 2008; 43: 100-111
7. Burgener FA, Violante MR. Comparison of hepatic VX2- carcinomas after intra-arterial, intraportal and intraparenchymal tumor cell injection. An angiographic and computed tomographic study in the rabbit. Invest Radiol 1979; 14: 410-414
8. Vossen JA, Buijs M, Syed L, Kutiyanwala F, Kutiyanwala M, Geschwind JF, Vali M. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intraarterial treatment with 3-bromopyruvate and chemoembolization. Clin Exp Metastasis 2008; 25: 811-817
9. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109
10. Yao X, Hu JF, Daniels M, Yien H, Lu H, Sharan H, Zhou X, Zeng Z, Li T, Yang Y, Hoffman AR. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res 2003; 9: 2719-2726
11. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasoundinduced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97: 473-483
12. Righi M, Giacomini A, Lavazza C, Sia D, Carlo-Stella C, Gianni AM. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. Lab Invest 2009; 89: 1063-1070